Core Viewpoint - Lisheng Pharmaceutical (002393.SZ) is expected to report significant growth in net profit for the first half of 2025, driven by market expansion and product volume increase, alongside investment income from its subsidiary Tianjin Central Pharmaceutical [1][2] Group 1: Financial Performance - For the first half of 2025, the company anticipates a net profit attributable to shareholders of between 330 million to 355 million yuan, representing a year-on-year increase of 222.42% to 246.85% [1] - The net profit after excluding non-recurring gains and losses is projected to be between 100 million to 115 million yuan, showing a year-on-year growth of 0.83% to 15.95% [1] Group 2: Market Strategy - The company has overcome the challenges posed by product price reductions by actively expanding its market presence and increasing product sales [1] - Lisheng Pharmaceutical has intensified its research and development efforts in the chronic disease sector, particularly focusing on cardiovascular products, and has accelerated the launch of new products [1] Group 3: Dividend Impact - The company will receive a cash dividend of 304 million yuan from its wholly-owned subsidiary Tianjin Central Pharmaceutical, based on its 12.15% stake in Tianshili Biological [1] Group 4: Competitive Position - Industry experts highlight that Lisheng Pharmaceutical demonstrates strong risk resistance due to its brand strength, cost control capabilities, and precise strategic positioning amid the normalization of centralized procurement and increasing industry differentiation [2] - The company is expected to maintain high growth in the second half of the year, with annual profitability potentially exceeding expectations due to the gradual realization of its innovative drug pipeline and new product launches [2]